[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580062":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":23,"locations":29,"responsibleParty":93,"collaborators":11,"id":95,"slug":11,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":11,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"VX-880","EXPERIMENTAL",null,[13],"Biological: Biological\u002FVaccine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Biological\u002FVaccine","Infused into the hepatic portal vein.",[9],[21,22],"Zimislecel","Formerly known as STx-02",[24],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Medical Information","CONTACT","617-341-6777","medicalinfo@vrtx.com",[30,43,52,62,71,79,88],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":11},"Perelman Center for Advanced Medicine - Endocrinology","RECRUITING","Philadelphia","Pennsylvania","19104","United States",{"type":38,"coordinates":39},"Point",[40,41],-75.16362,39.95238,{"lat":41,"lon":40},{"facility":44,"status":32,"city":45,"state":34,"zip":46,"country":36,"cosmosGeoPoint":47,"geoPoint":51,"contacts":11},"Montefiore Clinical and Translational Research Center - Endocrinology","Pittsburgh","15213",{"type":38,"coordinates":48},[49,50],-79.99589,40.44062,{"lat":50,"lon":49},{"facility":53,"status":32,"city":54,"state":55,"zip":56,"country":36,"cosmosGeoPoint":57,"geoPoint":61,"contacts":11},"UW University Hospital - Endocrinology","Madison","Wisconsin","53792",{"type":38,"coordinates":58},[59,60],-89.40123,43.07305,{"lat":60,"lon":59},{"facility":63,"status":32,"city":64,"state":11,"zip":11,"country":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":11},"Toronto General Hospital - Endocrinology","Toronto","Canada",{"type":38,"coordinates":67},[68,69],-79.39864,43.70643,{"lat":69,"lon":68},{"facility":72,"status":32,"city":73,"state":11,"zip":11,"country":65,"cosmosGeoPoint":74,"geoPoint":78,"contacts":11},"Vancouver General Hospital - Gordon and Leslie Diamond Health Care Centre","Vancouver",{"type":38,"coordinates":75},[76,77],-123.11934,49.24966,{"lat":77,"lon":76},{"facility":80,"status":32,"city":81,"state":11,"zip":11,"country":82,"cosmosGeoPoint":83,"geoPoint":87,"contacts":11},"King Abdullah International Medical Research Center (KAIMRC) - Riyadh - Endocrinology","Riyadh","Saudi Arabia",{"type":38,"coordinates":84},[85,86],46.72185,24.68773,{"lat":86,"lon":85},{"facility":89,"status":32,"city":81,"state":11,"zip":11,"country":82,"cosmosGeoPoint":90,"geoPoint":92,"contacts":11},"King Faisal Specialist Hospital & Research Centre - Riyadh - Endocrinology",{"type":38,"coordinates":91},[85,86],{"lat":86,"lon":85},{"type":94,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100580062",false,"NCT06832410","An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant","A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of VX-880 in Subjects With Type 1 Diabetes With a Kidney Transplant","Key Inclusion Criteria:\n\n* Clinical history of T1D with greater than or equal to (≥)5 years of insulin dependence\n* Taking a stable immunosuppression regimen of tacrolimus and mycophenolate mofetil, mycophenolate sodium, or sirolimus for at least 4 weeks\n* Consistent use of continuous glucose monitor (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study\n\nKey Exclusion Criteria:\n\n* Prior islet cell transplant, organ transplant (other than kidney transplant), or cell therapy, except prior pancreatic graft that failed within the first 4 weeks\n* Participants had \\>1 kidney transplant procedure\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years","65 Years",{"count":105,"type":106},10,"ESTIMATED","INTERVENTIONAL",[109],"PHASE3","This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.",[112,113],"Type 1 Diabetes","Kidney Transplant","2026-03-18",{"date":116,"type":117},"2026-03-23","ACTUAL",{"date":119,"type":117},"2025-03-31",{"date":121,"type":106},"2027-09-17",{"name":5,"class":6},7]